APO Research
Talk to an analyst

APO RESEARCH · REPORT

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchPhosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform include Novartis AG, GlaxoSmithKline Plc, Bayer AG, AstraZeneca Plc, PIQUR Therapeutics AG, Karus Therapeutics Ltd and Curis Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform, also provides the revenue of main regions and countries. Of the upcoming market potential for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform revenue, projected growth trends, production technology, application and end-user industry.

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Company

Novartis AG

GlaxoSmithKline Plc

Bayer AG

AstraZeneca Plc

PIQUR Therapeutics AG

Karus Therapeutics Ltd

Curis Inc

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Type

PQR-514

KA-2237

GSK-2636771

BAY-1082439

Others

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Application

Myelofibrosis

Renal Cell Carcinoma

Gastric Cancer

Metastatic Colorectal Cancer

Others

Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. PQR-514 Major Player Table 3. KA-2237 Major Player Table 4. GSK-2636771 Major Player Table 5. BAY-1082439 Major Player Table 6. Others Major Player Table 7. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Myelofibrosis Major Player Table 9. Renal Cell Carcinoma Major Player Table 10. Gastric Cancer Major Player Table 11. Metastatic Colorectal Cancer Major Player Table 12. Others Major Player Table 13. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Trends Table 14. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Drivers Table 15. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Opportunities and Challenges Table 16. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Restraints Table 17. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 18. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Region (2021-2026) & (US$ Million) Table 19. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Share by Region (2021-2026) Table 20. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Region (2027-2032) & (US$ Million) Table 21. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Share by Region (2027-2032) Table 22. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Players (US$ Million) & (2021-2026) Table 23. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Players (2021-2026) Table 24. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Key Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Key Players Headquarters & Area Served Table 26. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players, Product Type & Application Table 27. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players Establishment Date Table 28. Global Players Market Concentration Ratio (CR5 and HHI) Table 29. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 30. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 32. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 33. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Type (2021-2026) Table 34. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Type (2027-2032) Table 35. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 37. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 38. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Application (2021-2026) Table 39. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Application (2027-2032) Table 40. Novartis AG Company Information Table 41. Novartis AG Business Overview Table 42. Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 44. Novartis AG Recent Development Table 45. GlaxoSmithKline Plc Company Information Table 46. GlaxoSmithKline Plc Business Overview Table 47. GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 49. GlaxoSmithKline Plc Recent Development Table 50. Bayer AG Company Information Table 51. Bayer AG Business Overview Table 52. Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 54. Bayer AG Recent Development Table 55. AstraZeneca Plc Company Information Table 56. AstraZeneca Plc Business Overview Table 57. AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 59. AstraZeneca Plc Recent Development Table 60. PIQUR Therapeutics AG Company Information Table 61. PIQUR Therapeutics AG Business Overview Table 62. PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 64. PIQUR Therapeutics AG Recent Development Table 65. Karus Therapeutics Ltd Company Information Table 66. Karus Therapeutics Ltd Business Overview Table 67. Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 69. Karus Therapeutics Ltd Recent Development Table 70. Curis Inc Company Information Table 71. Curis Inc Business Overview Table 72. Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio Table 74. Curis Inc Recent Development Table 75. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 76. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 77. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 78. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 79. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 80. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026) & (US$ Million) Table 81. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (US$ Million) & (2027-2032) Table 82. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 83. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 84. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 85. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 86. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 87. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026) & (US$ Million) Table 88. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (US$ Million) & (2027-2032) Table 89. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 90. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 91. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 92. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 93. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 94. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 95. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 96. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 97. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 98. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Region (US$ Million) & (2021-2026) Table 99. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Region (US$ Million) & (2027-2032) Table 100. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026) & (US$ Million) Table 101. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032) & (US$ Million) Table 102. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026) & (US$ Million) Table 103. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032) & (US$ Million) Table 104. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026) & (US$ Million) Table 106. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (US$ Million) & (2027-2032) Table 107. Research Programs/Design for This Report Table 108. Authors List of This Report Table 109. Secondary Sources Table 110. Primary Sources List of Figures Figure 1. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Image Figure 2. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Share 2021 VS 2025 VS 2032 Figure 4. PQR-514 Image Figure 5. KA-2237 Image Figure 6. GSK-2636771 Image Figure 7. BAY-1082439 Image Figure 8. Others Image Figure 9. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size Share 2021 VS 2025 VS 2032 Figure 11. Myelofibrosis Image Figure 12. Renal Cell Carcinoma Image Figure 13. Gastric Cancer Image Figure 14. Metastatic Colorectal Cancer Image Figure 15. Others Image Figure 16. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size (US$ Million) & (2021-2032) Figure 17. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Share by Region: 2021 VS 2025 VS 2032 Figure 19. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players Revenue Share Top 10 and Top 5 in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Type (2021-2032) Figure 24. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 26. Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Application (2021-2032) Figure 27. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 28. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032) Figure 29. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032) Figure 30. North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Country (2021-2032) Figure 31. United States Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Canada Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Mexico Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 35. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032) Figure 36. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032) Figure 37. Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Country (2021-2032) Figure 38. Germany Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. France Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. U.K. Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Italy Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Spain Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Russia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Netherlands Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Nordic Countries Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032) Figure 48. China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032) Figure 49. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 50. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032) Figure 51. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032) Figure 52. Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Region (2021-2032) Figure 53. Japan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. South Korea Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. India Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Australia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Taiwan Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Southeast Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (2021-2032) & (US$ Million) Figure 60. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032) Figure 61. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032) Figure 62. SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Country (2021-2032) Figure 63. Brazil Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Argentina Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Chile Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Colombia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Peru Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Saudi Arabia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Israel Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. UAE Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Turkey Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Iran Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Egypt Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • PQR-514
  • KA-2237
  • GSK-2636771
  • BAY-1082439
  • Others
Applications
  • Myelofibrosis
  • Renal Cell Carcinoma
  • Gastric Cancer
  • Metastatic Colorectal Cancer
  • Others
Companies covered
  • Novartis AG
  • GlaxoSmithKline Plc
  • Bayer AG
  • AstraZeneca Plc
  • PIQUR Therapeutics AG
  • Karus Therapeutics Ltd
  • Curis Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Type
  3. 1.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 PQR-514
  5. 1.2.3 KA-2237
  6. 1.2.4 GSK-2636771
  7. 1.2.5 BAY-1082439
  8. 1.2.6 Others
  9. 1.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market by Application
  10. 1.3.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Myelofibrosis
  12. 1.3.3 Renal Cell Carcinoma
  13. 1.3.4 Gastric Cancer
  14. 1.3.5 Metastatic Colorectal Cancer
  15. 1.3.6 Others
  16. 1.4 Assumptions and Limitations
  17. 1.5 Study Goals and Objectives
2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Dynamics
  1. 2.1 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Trends
  2. 2.2 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Drivers
  3. 2.3 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Opportunities and Challenges
  4. 2.4 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Perspective (2021-2032)
  2. 3.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Growth Trends by Region
  3. 3.2.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Region (2021-2026)
  5. 3.2.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Players
  2. 4.1.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Players (2021-2026)
  3. 4.1.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Key Players Headquarters & Area Served
  7. 4.4 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players, Product Type & Application
  8. 4.5 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market CR5 and HHI
  11. 4.6.3 2025 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Tier 1, Tier 2, and Tier 3
5 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Type
  1. 5.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 5.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Type (2021-2032)
6 Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Size by Application
  1. 6.1 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  3. 6.3 Global Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 GlaxoSmithKline Plc
  8. 7.2.1 GlaxoSmithKline Plc Company Information
  9. 7.2.2 GlaxoSmithKline Plc Business Overview
  10. 7.2.3 GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  12. 7.2.5 GlaxoSmithKline Plc Recent Developments
  13. 7.3 Bayer AG
  14. 7.3.1 Bayer AG Company Information
  15. 7.3.2 Bayer AG Business Overview
  16. 7.3.3 Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Bayer AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  18. 7.3.5 Bayer AG Recent Developments
  19. 7.4 AstraZeneca Plc
  20. 7.4.1 AstraZeneca Plc Company Information
  21. 7.4.2 AstraZeneca Plc Business Overview
  22. 7.4.3 AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Plc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  24. 7.4.5 AstraZeneca Plc Recent Developments
  25. 7.5 PIQUR Therapeutics AG
  26. 7.5.1 PIQUR Therapeutics AG Company Information
  27. 7.5.2 PIQUR Therapeutics AG Business Overview
  28. 7.5.3 PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  29. 7.5.4 PIQUR Therapeutics AG Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  30. 7.5.5 PIQUR Therapeutics AG Recent Developments
  31. 7.6 Karus Therapeutics Ltd
  32. 7.6.1 Karus Therapeutics Ltd Company Information
  33. 7.6.2 Karus Therapeutics Ltd Business Overview
  34. 7.6.3 Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Karus Therapeutics Ltd Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  36. 7.6.5 Karus Therapeutics Ltd Recent Developments
  37. 7.7 Curis Inc
  38. 7.7.1 Curis Inc Company Information
  39. 7.7.2 Curis Inc Business Overview
  40. 7.7.3 Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Curis Inc Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Product Portfolio
  42. 7.7.5 Curis Inc Recent Developments
8 North America
  1. 8.1 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (2021-2032)
  2. 8.2 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 8.2.1 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026)
  4. 8.2.2 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032)
  5. 8.3 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032)
  6. 8.4 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  7. 8.4.1 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026)
  8. 8.4.2 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032)
  9. 8.5 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032)
  10. 8.6 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country
  11. 8.6.1 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026)
  13. 8.6.3 North America Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (2021-2032)
  2. 9.2 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 9.2.1 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026)
  4. 9.2.2 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032)
  5. 9.3 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032)
  6. 9.4 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  7. 9.4.1 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026)
  8. 9.4.2 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032)
  9. 9.5 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032)
  10. 9.6 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country
  11. 9.6.1 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026)
  13. 9.6.3 Europe Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (2021-2032)
  2. 10.2 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 10.2.1 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026)
  4. 10.2.2 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032)
  5. 10.3 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032)
  6. 10.4 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  7. 10.4.1 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026)
  8. 10.4.2 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032)
  9. 10.5 China Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (2021-2032)
  2. 11.2 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 11.2.1 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026)
  4. 11.2.2 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032)
  5. 11.3 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032)
  6. 11.4 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  7. 11.4.1 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026)
  8. 11.4.2 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032)
  9. 11.5 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032)
  10. 11.6 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country
  11. 11.6.1 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026)
  13. 11.6.3 Asia Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue (2021-2032)
  2. 12.2 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Type (2027-2032)
  5. 12.3 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Application (2027-2032)
  9. 12.5 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country
  11. 12.6.1 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst